微创医疗(00853)公布2025年业绩权益股东应占溢利4851.9万美元同比扭亏为盈

智通财经03-31

智通财经APP讯，微创医疗(00853)公布2025年业绩，收入约11.05亿美元，同比增长6%;公司权益股东应占溢利4851.9万美元，同比扭亏为盈;基本每股溢利2.59美分。经营性现金流同步转正，取得6910万美元。公告称，收入增长主要由于快速市场渗透及新产品收入贡献。报告期内，该集团“全球通”商业化平台取得积极进展，推动相关业务收入同比增长78.8%(剔除汇率影响)至1.639亿美元，并于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2623381255?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-31 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623381255","market":"us","top_or_hot":-1,"title":"微创医疗(00853)公布2025年业绩 权益股东应占溢利4851.9万美元 同比扭亏为盈","media":"智通财经","content":"<div>\n<p>智通财经APP讯，微创医疗(00853)公布2025年业绩，收入约11.05亿美元，同比增长6%;公司权益股东应占溢利4851.9万美元，同比扭亏为盈;基本每股溢利2.59美分。经营性现金流同步转正，取得6910万美元。公告称，收入增长主要由于快速市场渗透及新产品收入贡献。报告期内，该集团“全球通”商业化平台取得积极进展，推动相关业务收入同比增长78.8%(剔除汇率影响)至1.639亿美元，并于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1423450.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微创医疗(00853)公布2025年业绩 权益股东应占溢利4851.9万美元 同比扭亏为盈</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微创医疗(00853)公布2025年业绩 权益股东应占溢利4851.9万美元 同比扭亏为盈\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-31 22:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1423450.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，微创医疗(00853)公布2025年业绩，收入约11.05亿美元，同比增长6%;公司权益股东应占溢利4851.9万美元，同比扭亏为盈;基本每股溢利2.59美分。经营性现金流同步转正，取得6910万美元。公告称，收入增长主要由于快速市场渗透及新产品收入贡献。报告期内，该集团“全球通”商业化平台取得积极进展，推动相关业务收入同比增长78.8%(剔除汇率影响)至1.639亿美元，并于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1423450.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1585","symbol_name":"昨日强势股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1423450.html","article_id":"2623381255","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623381255","pubTimestamp":1774968534,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，微创医疗 公布2025年业绩，收入约11.05亿美元，同比增长6%;公司权益股东应占溢利4851.9万美元，同比扭亏为盈;基本每股溢利2.59美分。经营性现金流同步转正，取得6910万美元。报告期内，该集团“全球通”商业化平台取得积极进展，推动相关业务收入同比增长78.8%至1.639亿美元，并于报告期内实现盈亏平衡。报告期内，集团完成结构性心脏病业务与心律管理业务的战略整合.此次整合不仅优化了运营效率，亦使集团报表健康度明显提升。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1585":"昨日强势股","BK1589":"北水核心资产","00853":"微创医疗","BK1583":"高瓴概念","BK1100":"医疗保健设备"},"translate_title":"MicroPort Medical (00853) Announces 2025 Results Profit Attributable to Equity Shareholders of US$48.519 Million, Turning Loss to Profit YoY","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00853":1.5},"content_text":"智通财经APP讯，微创医疗(00853)公布2025年业绩，收入约11.05亿美元，同比增长6%;公司权益股东应占溢利4851.9万美元，同比扭亏为盈;基本每股溢利2.59美分。经营性现金流同步转正，取得6910万美元。公告称，收入增长主要由于快速市场渗透及新产品收入贡献。报告期内，该集团“全球通”商业化平台取得积极进展，推动相关业务收入同比增长78.8%(剔除汇率影响)至1.639亿美元，并于报告期内实现盈亏平衡。其中，手术机器人、结构性心脏病等核心业务的海外销售额分别取得286.6%与255.0%的同比扩大(剔除汇率影响)，该平台收入愈发多元化、业务协同持续加强，正日益成为集团增长的核心引擎。作为集团首个经历国家集中带量采购的核心产品线，心血管介入业务通过向“冠心病全解方案”的战略转型，已成功穿越行业周期，连续两年经调整净利润率超20%，保持稳健、良性态势，充分验证了其可持续的商业模式与经营韧性。告期内，集团创新成果系统覆盖“前沿探索-注册突破-产品落地-高级别循证”全链条：在探索与注册端，新增8款产品进入国家创新医疗器械绿色通道，累计达44款，连续十一年稳居行业首位;两款产品获美国FDA“突破性医疗器械”认定。在产品与循证端，多款重磅产品于全球获批上市;同时，自主研发的Firehawk®火鹰®冠脉支架的临床研究全文在《新英格兰医学杂志》(NEJM)发表，标志着研发实力获国际顶尖学术认可，为长期发展奠定了坚实根基。报告期内，集团完成结构性心脏病业务与心律管理业务的战略整合.此次整合不仅优化了运营效率，亦使集团报表健康度明显提升。更具战略意义的是，通过此次整合，集团强势切入心力衰竭治疗这一价值高地，致力于打造贯穿“监测—诊断—治疗—管理”全过程的全球化心衰专业器械平台，为集团开启了富潜力的全新增长曲线。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623381255","isCrawlerRequest":true}

微创医疗(00853)公布2025年业绩 权益股东应占溢利4851.9万美元 同比扭亏为盈

精彩评论

微创医疗(00853)公布2025年业绩权益股东应占溢利4851.9万美元同比扭亏为盈